CDKN2A and neoplasm: In multiple myeloma, miR-192 acts as a tumor suppressor by targeting IL-17Rs [98], and bioinformatic analyses suggest it connects with the bone marrow microenvironment by interacting with CDKN2A, influencing tumor progression [99].